Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended March 31, 2005
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2005 |
Three Months Ended Mar 31, 2004 |
Six Months Ended Mar 31, 2005 |
Six Months Ended Mar 31, 2004 |
|---|---|---|---|---|
| Revenues | $1,365,530 | $1,253,633 | $2,653,899 | $2,438,753 |
| Operating Income | $255,185 | $229,599 | $505,882 | $398,079 |
| Net Income | $188,150 | $165,160 | $383,501 | $290,562 |
| Diluted EPS (Continuing Ops) | $0.71 | $0.62 | $1.45 | $1.10 |
| Gross Profit Margin | 50.3% | 49.8% | 50.5% | 48.2% |
| Cash from Operations (6mo) | $450,417 (2005) vs $480,387 (2004) | |||
| Total Debt | $1,192,421 (Short-term: $141,052; Long-term: $1,051,369) | |||
| Cash and Equivalents | $825,497 (as of Mar 31, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% year-over-year for the quarter and 9% for the six-month period. Growth was driven by all three segments, with favorable foreign currency translation contributing approximately 3% to the quarterly increase.
- Profitability: Operating income rose 11% for the quarter and 27% for the six-month period. The six-month comparison is significantly aided by the absence of $45 million in Blood Glucose Monitoring (BGM) charges recorded in the prior year.
- Segment Performance:
- Medical: Revenue up 7% (quarter) and 9% (six months), driven by safety-engineered devices and Diabetes Care.
- Diagnostics: Revenue up 12% (quarter) and 8% (six months), with strong sales in flu diagnostic tests in Japan and instrument sales.
- Biosciences: Revenue up 8% (quarter) and 11% (six months), led by flow cytometry instrument sales.
- Accounting Changes: Adoption of SFAS No. 123(R) effective October 1, 2004, resulted in share-based compensation expenses of $16.6 million (quarter) and $28.1 million (six months), reducing net income.
- Debt Reduction: Total debt-to-capitalization ratio improved to 25.5% from 28.1% at the end of the prior fiscal year. The company redeemed $100 million of 8.7% Debentures in January 2005.
Guidance, Outlook, and Risks
- Full Year Guidance (Fiscal 2005):
- Gross Profit Margin: Expected to be approximately 50.5%.
- Selling & Admin Expenses: Expected to be 26.5% to 26.8% of revenues.
- R&D Expenses: Anticipated to increase about 12%.
- Capital Spending: Expected to be between $300 million and $325 million.
- Effective Tax Rate: Expected to be approximately 24%.
- Share Repurchases: The company repurchased approximately $225 million of common stock in the first six months. Authorization to repurchase an additional 10.2 million shares remains.
- Divestiture: The company plans to sell the Clontech unit (reported as Discontinued Operations). Results are excluded from continuing operations.
- Risks and Contingencies:
- Legal Proceedings: Ongoing litigation includes antitrust claims (Louisiana Wholesale Drug Company), patent infringement suits (Greiner, Dynovation), and environmental matters. Management believes claims are without merit but notes potential for material adverse effects if outcomes are unfavorable.
- Foreign Currency: Significant exposure to exchange rate fluctuations, particularly the Euro, which impacted reported revenue growth.
- Raw Materials: Higher costs for petroleum-based resins offset some margin improvements.
- Pension Funding: Discretionary contributions of $103 million reduced operating cash flow in the first six months.
Investor Verification Checklist
- Share-Based Compensation Impact: Verify the full-year impact of the new SFAS 123(R) accounting standard on earnings, estimated at 17 cents reduction in diluted EPS.
- Clontech Divestiture: Monitor the timeline and terms of the Clontech sale, as delays or unfavorable terms could affect future cash flows.
- Legal Reserves: Review the adequacy of reserves for pending litigation, specifically the antitrust and patent infringement cases, given the company's statement that losses are not estimable in all cases.
- Foreign Currency Sensitivity: Assess the company's hedging strategies and the potential impact of a strengthening U.S. dollar on future international revenue growth.
- Pension Obligations: Evaluate the funded status of pension plans and the potential for future discretionary contributions impacting cash flow.